Oprelvekin
Class: Hematopoietic Agents
- Growth Factors
VA Class: BL400
Chemical Name: 2-178-Interleukin 11 (human clone pXM/IL-11)
Molecular Formula: C854H1411N253O235S2
CAS Number: 145941-26-0
Brands: Neumega
Warning
Risk of serious allergic or hypersensitivity reactions, including anaphylaxis. (See Hypersensitivity Reactions under Cautions.)
Permanently discontinue therapy if an allergic or hypersensitivity reaction occurs.
Introduction
Biosynthetic (recombinant DNA-derived) form of human interleukin-11 (IL-11); a thrombopoietic growth factor that principally affects megakaryocytopoiesis.
Uses for Oprelvekin
Chemotherapy-induced Thrombocytopenia
Prevention of severe thrombocytopenia in adults with nonmyeloid malignancies receiving myelosuppressive antineoplastic therapy; designated an orphan drug by FDA for this use.
Reduces the need for platelet transfusions following myelosuppressive chemotherapy.
Indicated for patients at high risk (as judged by the clinician) of developing severe chemotherapy-induced thrombocytopenia.
Not indicated for use in patients undergoing myeloablative chemotherapy†. (See Fluid Retention under Cautions.)
Efficacy not established in patients receiving chemotherapy regimens of >5 days duration or regimens associated with delayed myelosuppression (e.g., nitrosoureas, mitomycin-C)†.
Oprelvekin Dosage and Administration
Administration
Sub-Q Administration
Administer by sub-Q injection daily. Give dose at approximately the same time each day.
Administer as a single injection into the abdomen, thigh, hip, or upper arm. Rotate injection sites.
Do not rub injection sites.
Initiate oprelvekin 6–24 hours following completion of chemotherapy. Safety and efficacy of administering immediately prior to or concurrently with chemotherapy, or at the time of the expected platelet nadir, not established.
If a dose is missed, resume next scheduled dose at the appropriate time; do not double a dose.
Intended for use under the guidance and supervision of a clinician, but may be self-administered if clinician determines that patient and/or caregiver is competent to prepare and safely administer the drug.
Consult manufacturer's labeling for specific instructions on reconstitution, dilution, and administration.
Reconstitution
Reconstitute vial labeled as containing 5 mg of oprelvekin powder for injection with 1 mL of sterile water for injection to provide a solution containing oprelvekin 5 mg/mL.
During reconstitution, direct diluent towards side of vial. Gently swirl to dissolve powder; do not shake.
Vials are for single use only; discard any unused solution after withdrawal of dose and do not re-enter or reuse vial.
Administer as soon as possible or within 3 hours after reconstitut..
